Risk Evaluation and Mitigation Strategies (REMS) were originally developed for drugs that cause birth defects, like Roche’s acne medicine Accutane or Celgene’s cancer pill Thalomid, also known as thalidomide. But now they have become the new hurdle for companies hoping to market medicines.
via blogs.forbes.com
1 comment:
Thank you for another great article. Where else could anyone get that kind of information in such a perfect way of writing.
Post a Comment